MINT-LEVOCARB TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

LEVODOPA; CARBIDOPA

Disponible depuis:

MINT PHARMACEUTICALS INC

Code ATC:

N04BA02

DCI (Dénomination commune internationale):

LEVODOPA AND DECARBOXYLASE INHIBITOR

Dosage:

100MG; 25MG

forme pharmaceutique:

TABLET

Composition:

LEVODOPA 100MG; CARBIDOPA 25MG

Mode d'administration:

ORAL

Unités en paquet:

100/500

Type d'ordonnance:

Prescription

Domaine thérapeutique:

DOPAMINE PRECURSORS

Descriptif du produit:

Active ingredient group (AIG) number: 0210315003; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2016-09-23

Résumé des caractéristiques du produit

_Page 1 of 30_
PRODUCT MONOGRAPH
Pr
MINT-LEVOCARB
levodopa and carbidopa tablets, House Std.
100 mg/10 mg
100 mg levodopa and 10 mg carbidopa
100 mg/25 mg
100 mg levodopa and 25 mg carbidopa
250 mg/25 mg
250 mg levodopa and 25 mg carbidopa
Antiparkinson Agent
Mint Pharmaceuticals Inc.
Date of Preparation:
1093 Meyerside Dr., Unit #1
21 September 2016
Mississauga, Ontario
L5T 1J6 SUBMISSION CONTROL NO: 188795
_Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE
REACTIONS....................................................................................................8
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND
ADMINISTATION.................................................................................11
OVERDOSAGE
................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................15
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................15
PART II: SCIENTIFIC INFORMATION
...............................................................................16
PHARMACEUTICAL
INFORMATION..........................................................................16
CLINCIAL TRIALS
..............................................................